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British Gynaecological Cancer Society (BGCS) Epithelial Ovarian / 
Fallopian Tube / Primary Peritoneal Cancer Guidelines: 
Recommendations for Practice 
 
Authors: Christina Fotopoulou, Marcia Hall, Derek Cruickshank, Hani Gabra, Raji Ganesan, Cathy 
Hughes, Sean Kehoe, Jonathan Ledermann, Jo Morrison, Raj Naik, Phil Rolland, Sudha Sundar 
International reviewers: David Cibula, Robert Coleman, Nicoletta Colombo, Michael Friedlander, 
Denis Querleu 
The remit of this guideline is to collate and propose evidence-based guidelines for the management 
of epithelial ovarian-type cancers (ovary, fallopian tube or peritoneal origin) and borderline tumours. 
This document covers all epithelial cancers with any histological subtype.  
 
Grades of recommendations 
 
Recommendations are graded as per the Royal College of Obstetricians and Gynaecologists 
document. Clinical Governance Advice No. 1: Guidance for the Development of RCOG Green-top 
Guidelines, available on the RCOG website at: 
  
https://www.rcog.org.uk/en/guidelines-research-services/guidelines/clinical-governance-advice-1a/ 
 
See appendix for more details. 
 
Evidence was searched in the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane 
Library 2010, Issue 3), MEDLINE and EMBASE up to August 2014, registers of clinical trials, abstracts 
of scientific meetings, reference lists of included studies and contacted experts in the field. 
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Guideline development process 
1) These guidelines are the property of the BGCS and the Society reserves the right to 
amend/withdraw the guidelines.  
2) The guideline development process is detailed below: 
a. Chair, officers, council and guidelines committee (GC) nominated a lead for each 
guideline topic; 
b. Lead then identified a team called the guideline team (GT) to develop the 1st draft; 
c. 1st draft was submitted to the GC; 
d. GC approved draft and recommended changes; 
e. Changes were accepted by the GT who produced the guidelines; 
f. 2nd draft was then submitted to council members and officers; 
g. Council and officers approved 2nd draft and recommended changes; 
h. Changes were then accepted by GC and GT; 
i. 3rd draft was sent to national and international peer review; 
j. GC and GT then made changes based on peer review comments; 
k. 4th draft was sent back to council for approval; 
l. 4th draft was sent to BGCS members for feedback; 
m. GC and GT then made changes based on members’ feedback; 
n. 5th draft was sent to public consultation including patient support groups; 
o. GC and GT then made changes based on non-members’ feedback; 
p. Final draft approved by council and officers. 
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1. Introduction 
Incidence, prevalence and clinical presentation 
Epithelial ovarian cancer (EOC) is the 6th most common cancer among women in the UK (2014) and 
accounts for 4% of all new cases of cancer in females: it has the highest mortality of all 
gynaecological cancers, accounting for 6% of all cancer deaths in women  
(http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/ovarian-cancer - heading-Zero).  A total of 7,378 new cases were reported in the UK in 2014 
(http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/ovarian-cancer - heading-Zero).  The crude incidence rate is 23 new ovarian cancer cases for 
every 100,000 females in the UK, with higher rates in Wales and lower rates in Northern Ireland 
compared with England. EOC occurs predominantly in post-menopausal women, peaking in the 60-
64 years’ age group. 
Despite the improvements in cancer detection, through increased use of imaging and CA125 
measurement, more than 70% of patients with newly diagnosed EOC will present with extra-pelvic, 
and therefore advanced, disease (FIGO stage-III or IV). Approximately one third of EOC-patients in 
England presented as an emergency before 2006, with up to 74% of these patients not subsequently 
receiving any active cancer treatment. 
(http://www.ncin.org.uk/publications/data_briefings/routes_to_diagnosis).  However, rates of 
emergency presentations have fallen (from 31% in 2006 to 26% in 2013) and two week wait (TWW) 
referrals have increased significantly (from 22% in 2006 to 31% in 2013). Overall, 36% of EOC 
patients die within the first year of presentation.(1)  
Diagnosis 
Presenting symptoms 
Symptoms associated with ovarian cancer (particularly when present for more than a year and 
occurring more than 12 times per month) are persistent abdominal distension, abdominal 
bloating, early satiety and/or loss of appetite, pelvic or abdominal pain, and increased urinary 
urgency and/or frequency. Other symptoms may include: postmenopausal bleeding; unexplained 
weight loss; fatigue or changes in bowel habit.(2)  
A number of case–control studies investigating symptoms in women with ovarian cancer and 
comparing them to symptoms in women without ovarian cancer demonstrate that patients with 
ovarian cancer are symptomatic for a variable period before diagnosis and challenge the perception 
of ovarian cancer as the "silent killer".(3)  
Diagnostic methods - Current guidance 
Sequential testing with CA125 and ultrasound in women presenting to primary care with 
symptoms suggestive of ovarian cancer is recommended. This is especially so in women over the 
age of 50. Urgent referral to secondary care is indicated, if both tests are abnormal, or if women 
present to primary care with a pelvic or abdominal mass.(2) 
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In the UK, recommendations for diagnosis and referral are based on National Institute for Health and 
Clinical Excellence (NICE) guidelines on the Recognition and Initial Management of Ovarian Cancer 
(2) and the Scottish Intercollegiate Guidelines Network guidelines on epithelial ovarian cancer.(3)  
The prospective Canadian Diagnosing Ovarian Cancer Early (DOVE) study investigated whether open-
access assessment would increase the rate of early-stage diagnosis of ovarian cancer.(4)The analysis 
of 1455 women demonstrated that DOVE patients presented with less tumour burden than the 
general population of patients, had significantly lower CA125 levels and attained significantly higher 
complete tumour resection rates (due to the lower tumour burden) even though no stage shift per se 
was noted. The investigators concluded that because the development of most (high grade serous) 
ovarian cancers is thought to be extra-ovarian, early diagnosis programmes should ideally aim to 
identify low-volume disease, rather than early-stage disease, and that diagnostic approaches should 
be modified accordingly.  
2. Screening and prevention 
Risk Stratification 
Protective factors include combined oral contraceptive pill use, pregnancy, sterilization/tubal ligation 
and hysterectomy. Factors associated with increased risk include family history associated with 
mutations in the BRCA1, BRCA2 or mismatch repair genes (Lynch Syndrome), nulliparity or first birth 
after age 35 years, early menarche, and late menopause. 
Primary care 
CA125 and pelvic ultrasound scan (+/- TVS as indicated) should be considered the initial 
investigations for post-menopausal women presenting with signs or symptoms of ovarian cancer 
(Grade B). 
 
Women with an RMI of ≥250 should have further investigations and be referred to the specialist 
gynaecological centre MDT (Grade B). 
 
There is currently no role for organized screening programmes in women considered at low risk of 
development of ovarian cancer (Grade A) 
 
The role of ovarian cancer screening in women at high risk of ovarian cancer has yet to be 
established (Grade B) 
  
Clinical examination and serum CA125 measurement should be considered in women with 
symptoms suggestive of ovarian cancer. If the CA125 is ≥35 IU/ml, or if a pelvic mass or other 
abnormality is identified at examination, an ultrasound scan of the abdomen and pelvis should be 
considered. For women with a normal CA125 <35 IU/ml, or a CA125 ≥35 IU/ml associated with a 
normal ultrasound, careful clinical assessment for other causes for their symptoms is required. 
Women in this group should return to their GP, if their symptoms become more frequent and/or 
persistent. (2) 
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The American Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomised 
Controlled Trial demonstrated that screening asymptomatic postmenopausal women with a single 
threshold value of CA125 does not result in reduction of mortality, despite 13 years of long term 
follow up. Diagnostic evaluation following a false-positive screening test result was associated with 
complications.(5, 6). 
 
The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial randomised 202,000 women 
to observation alone, multimodal screening (MMS), with an algorithm based on serial values of 
CA125 and follow on transvaginal ultrasound scanning (TVS) for abnormal results, or serial TVS alone. 
The results showed no reduction in mortality in the primary analysis, but a possible reduction in 
mortality after exclusion of prevalent cases after 7 years of follow-up. Long-term data and cost-
effectiveness data are awaited.(7) 
Approximately 1.3% of women in the general population will develop ovarian cancer in their lifetime 
(4).  By contrast, according to the most recent estimates 39% of women who inherit a harmful BRCA1 
mutation (5, 6) and 11-17% of women who inherit a harmful BRCA2 mutation will develop ovarian 
cancer by age 70. (8, 9) The UK Familial Ovarian Cancer Screening Study (UKFOCCS) study evaluated a 
strategy of annual ultrasound and CA125 measurement in 3,653 women considered at >10% risk of 
development of ovarian cancer and who declined risk-reducing salpingo-oophorectomy (RRSO). The 
positive and negative predictive values of incident screening were 25.5% (95% CI, 14.3 to 40.0) and 
99.9% (95% CI, 99.8 to 100), respectively. This study is still on-going and work up to 2018 will 
evaluate a 4-monthly screening strategy with CA125 and ultrasound in this group.(10) RCOG 
guidelines (2015) did not recommend routine screening in these women 
(https://www.rcog.org.uk/globalassets/documents/guidelines/scientific-impact-papers/sip48.pdf). 
Risk-reducing salpingo-oophorectomy (RRSO) prevents development of epithelial ovarian cancer 
and reduces mortality in women at high risk for epithelial ovarian cancer (Grade B).   
 
Prospective multicentre cohort studies have demonstrated that risk-reducing salpingo-
oophorectomy (RRSO) is associated with a lower risk of EOC, first diagnosis of breast cancer, all-
cause mortality, breast cancer–specific mortality, and ovarian cancer–specific mortality in BRCA1- 
and BRCA2-mutation carriers, although there still is a residual risk for peritoneal cancer.(11, 12) On-
going studies are evaluating the role of opportunistic salpingectomy in the prevention of ovarian 
cancer in low risk women.(13)  
Tumour markers and Malignancy Indices  
Tumour markers are not diagnostic tests, but may be helpful in establishing diagnosis and providing 
baseline values that may be of use during follow up.(14)  
 
Prospectively acquired evidence from the United Kingdom Collaborative Trial of Ovarian Cancer 
Screening Cancer (UKCTOCS) - with 46,237 women triaged using MMS in whom serial CA-125 
measurements were interpreted via the risk of ovarian cancer algorithm (ROCA®) - has shown that 
screening by using ROCA® doubles the number of screen-detected EOC compared with a fixed cut off 
of 35 IU/ml. 
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Caution must be exercised in reassuring women with a single normal CA125 measurement and a 
focus more on interpreting trends, along with the clinical picture and imaging findings, is likely to 
define the standard of care in the future.(15)  
3. Secondary care and initial pre- treatment assessment 
 
In women below 40 years of age with suspected ovarian cancer, measure alpha fetoprotein (AFP), 
and hCG (human Chorionic Gonadotropin), in addition to CA125, to identify women with non 
epithelial ovarian lesions (Grade C) . Inhibin should be measured at a presumed diagnosis of a 
granulosa cell tumor, even though logistically it takes potentially longer to access the results.  
 
Secondary care 
 
Following referral of a patient with a mass suspicious of ovarian cancer to secondary care, an 
expansion of the tumour marker panel may facilitate diagnosis.  
 
Where CA125 is elevated, a preoperative CA125/CEA ratio < 25 , especially in combination with an 
elevated CA19-9, may indicate peritoneal carcinomatosis from a gastrointestinal tumour and bi-
directional gastrointestinal endoscopy should be considered prior to upfront primary debulking 
surgery.[Grade B] 
 
HE4 (human epididymis protein 4) has shown promising diagnostic and prognostic value in triaging 
younger women, with HE4 not raised in cases of pelvic inflammatory disease and endometriosis 
despite CA125 elevation being observed. (16-18)  
 
Large prospective studies from the International Ovarian Tumour Analysis consortium (IOTA) suggest 
that using simple “M”(malignant) and “B” (benign) ultrasonographic rules to characterise ovarian 
masses is highly accurate. Using these simple rules, the reported sensitivity for malignancy was 95%, 
specificity 91%, positive likelihood ratio 10.37, and negative likelihood ratio 0.06. (19) The accuracy 
of the IOTA ultrasonographic rules has been demonstrated in secondary care, predominantly with 
specialists in ultrasonography and their wider use remains under evaluation in the UK 
(http://www.birmingham.ac.uk/rockets). Results from an on-going study to evaluate the best serum 
diagnostic tests and ultrasound models to detect ovarian cancer are awaited.  
Advised examinations prior to deciding treatment 
In patients with presumed ovarian cancer, radiological staging will provide further information 
about the extent of disease and potential distant metastases or secondary cancers. (Grade C) 
 
CT prediction of suboptimal cytoreduction is not sufficiently reliable and in the absence of 
favourable data from larger, prospective trials should not be used alone to decide management. 
(Grade B) 
 
MRI should not be routinely used for assessing women with suspected ovarian cancer outside of 
clinical trials, but can be useful where the results of the USS are not helpful in confirming a 
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diagnosis, especially in young women with a solitary pelvic mass who want a fertility sparing 
approach. (Grade B) 
 
PET CT is not recommended for routine preoperative staging in the NHS outside a clinical trial. 
(Grade C) 
 
CT imaging of the thorax, abdomen and pelvis is recommended to help define the extent of disease 
and to aid in surgical planning. However, retrospective data have shown that CT cannot accurately 
predict fine nodule peritoneal carcinomatosis, and therefore mitigate against suboptimal 
cytoreduction, and that it is not always reliable and reproducible.(2, 20) Current prospective imaging 
trials are underway to prospectively assess the predictive value of novel imaging techniques in 
determining operability.  
 
CT has significant value in excluding distant macroscopic disease spread, including 
intraparenchymal liver or lung metastases and retroperitoneal node involvement, and in excluding 
synchronous cancers from other sites or thromboembolic events that may alter management. 
(Grade B) 
 
Current national guidance recommends that MRI should not routinely be used for assessing women 
with suspected ovarian cancer, but may be used as a problem-solving tool and adjunct to other 
imaging modalities. There is also no evidence based value in the routine use of specialized imaging 
techniques such as positron emission tomography–computed tomography (PET CT),  although it may 
be useful as a problem-solving tool in highly specialised situations (for example in the evaluation of 
thoracic/mediastinal lymph nodes where secondary intra-abdominal debulking for relapsed disease 
is under consideration).(21) 
 
Diffusion weighted MRI may have a future role in the description of tumour dissemination patterns 
and assessment of operability, but prospective evidence data for that are warranted.(22)  
Cytological/Histological Diagnosis 
If offering cytotoxic chemotherapy to women with suspected advanced ovarian cancer first obtain 
a confirmed tissue diagnosis by histology in all but exceptional cases. (Grade C)(2) 
 
Only commence cytotoxic chemotherapy for suspected advanced ovarian cancer on the basis of 
positive cytology alone and imaging and without histological confirmation in exceptional cases and 
where obtaining a tissue sample would be inappropriate. A discussion of such cases at the 
multidisciplinary team meeting including a careful consideration of the risks and benefits should 
be documented (Grade C). 
 
All patients with histology / cytology showing suspected or actual carcinoma of gynaecological origin 
should be reviewed at a gynaecology multidisciplinary team (MDT) meeting. 
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Histological diagnosis is not mandatory prior to upfront debulking surgery if the clinical picture, 
imaging and tumour marker profile are highly suggestive of epithelial ovarian cancer (CA125:CEA 
ratio >25:1).  
 
If ascites is sent for cytological analysis, the absence of malignant cells does not exclude ovarian 
malignancy, especially in the presence of inflammation (Grade B).(23, 24) 
 
The use of immunohistochemistry on a cell block can be of help in such cases if sufficient atypical 
cells are present to allow for separation from background cells and interpretation of patterns of 
staining. This is of high value to aid tissue diagnosis in mixed or undifferentiated tumours. 
  
Where upfront cytotoxic chemotherapy is offered to women with suspected advanced ovarian 
cancer, histological tissue diagnosis via image guided biopsy or laparoscopy is mandatory in all but 
exceptional cases. Cytology alone, together with a CA125/CEA ratio of >25:1 may be sufficient in 
patients with poor performance status (PS 3,4) and where biopsy is not feasible. (Grade C) 
 
In the majority of the cases tissue can be safely obtained through image guided biopsy. The value of 
laparoscopy in the assessment of operability and impact on overall surgical and clinical outcome of 
advanced ovarian cancer has not been established in prospective randomised trials . Emerging 
research protocols utilize laparoscopically obtained multiple intra-abdominal biopsies to define 
molecular biological profile of each individual patient but the survival benefit of this approach has 
not been proven in any prospective randomised trials.  
 
The routine use of laparoscopy to obtain pre-treatment histology and to assess the operability of 
disease is not recommended. (Grade B)   
 
Data to support laparoscopic assessment to determine tumour resectability is limited and suffers 
from verification bias.(2)  In a Cochrane review, assessing the accuracy of laparoscopy to determine 
tumour resectability in ovarian cancer, only two studies performed laparoscopy and laparotomy in all 
patients. (25) The other studies only performed a laparotomy when it was thought that an optimal 
result was feasible. It is therefore not possible to draw definitive conclusions about the sensitivity of 
laparoscopy. Three studies developed or validated a prediction model including laparoscopy. Using a 
prediction model did not increase the sensitivity and resulted in more patients undergoing 
suboptimal surgery. 
A multidisciplinary discussion within a quorate MDT as constituted along national guidelines is 
fundamental to the appropriate management of each individual patient and should be documented 
prior to a decision to operate, offering chemotherapy or palliative treatment in all but exceptional 
cases, such as emergency presentations between meetings, and the management of these cases 
should be agreed and described in a departmental gynaecological cancer operational document. 
Significance and caveats of cytology 
In about two thirds of patients with known ovarian carcinoma, malignant cells are seen in the ascitic 
fluid. However, there are strong reservations about using peritoneal or ascitic cytology without 
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histological confirmation in the primary diagnosis of ovarian cancer. Cytological preparations lack 
architectural patterns and false positive tests may be obtained from serous borderline tumours and 
from exfoliation of other cells, such as epithelial cells from Müllerian rests and reactive mesothelial 
cells, which may be mistaken for carcinoma. This problem may be partially resolved through 
constructing cell blocks and performing appropriate immunohistochemistry, but despite this, the use 
of cytology in the diagnosis of ovarian carcinoma has a high false negative rate and is operator 
dependent.  
Histological confirmation is recommended prior to treatment with chemotherapy. In exceptional 
cases, where obtaining material for histology is not possible or is associated with a high risk due to 
the poor performance status or co-morbidities of the patient, cytology may be used alone in 
establishing a pre-chemotherapy diagnosis.  
In women with pleural effusions, aspiration and examination for malignant cells and cytology should 
be considered to confirm staging (preferably with immunohistochemistry on cell block). (23, 24). 
 
When used in trial settings, cytological preparations are suboptimal for archiving, tissue microarrays 
and some molecular testing. 
4. Pathology and genetics 
The provision of a minimum set of clinical information on the histopathology request form is 
crucial to ensure a histopathology report of high enough quality for the accurate diagnosis and 
appropriate management. (Grade D) 
Frozen section may be performed, if the result will alter the intra-operative management although 
there are limitations to the technique. (Grade B) 
Clinical information required on the specimen request form 
The Royal College of Pathology guidelines for reporting ovarian carcinomas mandate the provision of 
minimum clinical details to include demographics, clinical presentation, results of previous biopsies, 
radiological investigations for tumour staging, and details of the surgical procedures performed. It is 
desirable to include details of any family history of cancer and relevant hormonal therapy. The 
nature of surgical specimens from multiple sites should be carefully recorded and the specimen pots 
labelled to correspond to the specimen details on the request form and appropriately labelled as to 
site of origin. 
Primary site assignment 
The origin of high-grade serous ovarian carcinoma (HGSC) has been the subject of intense study. The 
distal fallopian tube has emerged as the likely site of origin for most HGSC. (26) This observation is, in 
great part, attributable to the use of sampling protocols that thoroughly examine the distal fallopian 
tube and also due to the greater number of specialist pathologists with a sub-specialty interest in 
gynaecological pathology. The discovery of serous tubal intraepithelial carcinoma (STIC) in women 
with BRCA1 or BRCA2 mutations following risk-reducing salpingo-oophorectomies (RRSO) and in 
women with advanced ovarian carcinoma lead to the hypothesis that the natural history of pelvic 
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HGSC might involve an origin in most cases of the distal fimbria of the fallopian tube. Identification of 
STIC in 18% to 60% of cases of advanced/symptomatic HGSC supports this assertion. STIC lesions are 
characterized by DNA damage, TP53 mutation, and progressive molecular abnormalities that are also 
seen in high-grade serous carcinoma. An origin from epithelial inclusion cysts in the ovary has been 
proposed as a potential explanation as site of origin in the cases where complete examination of the 
fallopian tube does not reveal STIC. A consensus statement on primary site assignment in tubo-
ovarian HGSC has been made. (27) 
Immunohistochemical features of HGSC 
HGSC of tubo-ovarian and peritoneal origin have similar morphological and immunohistochemical 
features. HGSC can be arranged in papillary, glandular or solid architecture. HGSC exhibits moderate 
to marked nuclear atypia and greater than 12 mitoses per 10 high power fields. Necrosis and 
multinucleate cells are often present. The distinction between low-grade and high-grade serous 
carcinoma is based on cytological, not architectural, features. On immunohistochemistry, HGSC of 
tubo-ovarian and peritoneal origin are typically positive for CK7, WT1, PAX8, oestrogen receptor and 
CA125. They do not stain for CK20, CEA and CDX2. P53 shows aberrant expression, characterized by 
either diffuse strong positive staining in greater than 75% of cells or by complete lack of staining.  
Genetics 
Women with HGSC or G3 endometrioid ovarian adenocarcinoma have >10% risk of an underlying 
BRCA mutation and should be offered clinical genetics counselling and testing. (GRADE C) 
Recently it has been shown that ~18% (much higher in certain groups such as Ashkenazi Jews) of the 
population of women presenting with high grade serous or G3 endometrioid ovarian 
adenocarcinoma carry a germline BRCA mutation, 44% of whom have no positive family history.(28) 
Every patient with a current or past histological diagnosis of HGSC or G3 endometrioid ovarian 
carcinoma therefore qualifies for BRCA counselling and testing, as advised by NICE, which should be 
discussed and offered .(29)  The advantages of BRCA testing include: 
 
 Prognostic information, as this group is likely to have longer remission periods;  
 Predictive genetic testing and advice for other family members who are at risk of inheriting 
BRCA, about screening and risk-reducing surgery to minimise their chance of developing 
cancers; 
 PARP inhibitor treatment may offer longer-term remission and response for some BRCA-
mutation carriers. (30) Olaparib is an option for treating women with relapsed, platinum-
sensitive ovarian cancer who have BRCA1 or BRCA2 mutations and whose disease has 
responded to platinum-based chemotherapy, if they have had 3 or more courses of platinum-
based chemotherapy. (31) 
Special histological features of different subtypes 
Endometrioid Carcinoma of ovary 
 
These represent the second most common form of ovarian EOC and account for 10 – 15% of ovarian 
EOC. A significant number are associated with endometriosis in the ovary, or elsewhere in the pelvis, 
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and about 15% of cases have synchronous endometrial carcinomas. (32, 33) Endometrioid 
carcinomas of the ovary can show a variety of patterns of which an adenofibromatous pattern and 
squamous metaplasia are amongst the confirmatory endometrioid features.  The clinical 
management of G3 endometrioid ovarian cancers corresponds to that described for high-grade 
serous cancer (HGSC). 
 
Clear cell carcinoma 
 
Clear cell carcinoma is the subtype most frequently associated with pelvic endometriosis, 
paraneoplastic hypercalcaemia and venous thromboembolism. The tumour is composed of clear, or 
hobnail, cells arranged in papillary, glandular or solid patterns in a hyaline stroma. The cells are 
typically WT1-/p53 wild type and show staining with napsin A. They mostly lack expression of 
oestrogen and progesterone receptors.(34) Clear cell carcinoma of the ovary is managed in an 
identical manner to HGSC, but is less responsive to chemotherapy than serous and endometrioid 
histological subtypes.  
 
Carcinosarcoma 
 
Carcinosarcoma is a rare gynecological neoplasm that may arise in any region of the gynaecological 
tract and which accounts for 1% to 3% of ovarian cancers.  It belongs to the category of mixed 
Müllerian tumours, with both epithelial and mesenchymal components being malignant. They were 
previously called malignant mixed Müllerian tumours (MMMT). Recent immunohistochemical and 
molecular findings support the hypothesis that gynecological carcinosarcomas represent metaplastic 
carcinomas.  Cell lines established from carcinosarcomas are able to differentiate into epithelial or 
mesenchymal components, or a combination of the two, (35) and immunohistochemistry 
demonstrates the expression of epithelial markers in the sarcomatous component of 
carcinosarcoma. Clonality patterns, genomic analysis, and loss of heterozygosity studies have shown 
that carcinomatous and sarcomatous components of these tumours share common genetic 
alterations, including aberrant p53 expression and occasionally germline mutation of BRCA2.(36, 37) 
The transformation of a carcinoma to a sarcoma in these tumours may represent a 
transdifferentiation, as seen in epithelial-to-mesenchymal transition phenomena. (38) 
Overall, the prognosis for carcinomosarcoma is worse than for high-grade ovarian carcinoma of a 
similar FIGO stage (39).  Most (90%) present with advanced disease.  At present they should be 
managed in the same way as HGSC. 
5. Surgical treatment 
Suspected or Confirmed Early Stage Disease 
Women with suspected epithelial ovarian cancer should undergo surgery at a cancer centre by 
specialised surgeons who are core members of a specialist MDT. (Grade B) 
Women requiring chemotherapy should be treated by a medical or clinical oncologist who is a core 
member of a specialist MDT. (Grade D) 
Affected women should have an identified key worker and responsible clinician.  (Grade D) 
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Treatment summaries, including symptoms of recurrence, should be provided to all women on 
completion of each episode of treatment and on discharge to primary care. (Grade D) 
The aim of surgery for early ovarian cancer (stage I and II) is complete macroscopic tumour 
resection and adequate surgical staging.  (Grade A) 
Patients suitable for fertility-sparing surgery should be identified by the MDT and the pros and 
cons of this discussed with them, so that they can make an informed choice. (Grade D) 
Early stage disease may be an unexpected post-operative histological finding in cases that have 
been managed as a benign condition.  A re-staging procedure by a gynaecological oncologist could 
be advised to establish stage and possibly define type or necessity of adjuvant treatment (Grade 
B).  
Adequate (non fertility-sparing) primary surgery for apparent early stage ovarian cancer consists of 
peritoneal washings/ascitic sampling taken prior to manipulation of the tumour, bilateral salpingo-
oophorectomy, total hysterectomy, multiple peritoneal biopsies from the para-colic spaces, and 
the sub-diaphragmatic spaces bilaterally, omentectomy, and pelvic and bilateral para-aortic lymph 
node assessment up to the level of the insertion of the ovarian vessels in the absence of peritoneal 
dissemination. (Grade B)  
The rate of positive lymph nodes in mucinous tumours is very low and lymph node dissection is 
therefore not warranted.  However, appendicetomy should be performed where a mucinous 
tumour is suspected. (GRADE B) 
Women with suspected ovarian cancer should be referred to gynaecological oncology centres for 
treatment.  A meta-analysis of retrospective studies assessing over 9000 women suggested that 
treatment of women in institutions with gynaecological oncologists on site may prolong survival, 
compared to community or general hospitals (HR 0.90; 95% CI 0.82 to 0.99)(40) This supports 
guidelines in the UK on Improving Outcomes in Gynaecological Cancers (41, 42). 
Full surgical staging provides useful prognostic information and may affect subsequent treatment.  
The survival value of full surgical staging in apparent stage I ovarian cancer is extrapolated from data 
from RCTs assessing the benefit of adjuvant chemotherapy in early stage disease (43,44). 
Depending on the histological grade and subtype, up to 30% of the patients with apparently early 
epithelial ovarian cancer will be upstaged after comprehensive surgical staging. (46, 47) Cass and 
colleagues showed in 96 patients with grade 3 tumours and gross disease confined to one ovary, that 
15% had microscopically positive lymph nodes. (48)  Among these patients, 50% had positive pelvic 
nodes, 36% had positive para-aortic node and both were positive in 14% of the cases. Maggioni and 
colleagues reported on a prospective randomised trial of systematic lymphadenectomy in patients 
with ovarian cancer macroscopically confined to the pelvis. Positive nodes were detected in 22% of 
patients undergoing systematic lymphadenectomy compared to only 9% of patients who underwent 
merely a sampling (p=0.007). Although a trend for improved PFS and OS was observed for the 
lymphadenectomy group compared to control, the study lacked the statistical power. (49) Increasing 
evidence shows that the rate of positive lymph nodes in stage I mucinous cancer is extremely low 
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(near 0%), and there is no value in performing this given the potential morbidity of such the 
procedure. (50-52) 
 
When young women are affected by early stage epithelial ovarian cancer, fertility-sparing surgery 
can be considered following thorough discussion with the patient about the potential risk of 
recurrent epithelial ovarian cancer. Patients with grade 1 or 2 mucinous, serous, endometrioid, or 
mixed histology and FIGO stage IA or stage IC with unilateral ovarian involvement may be eligible for 
uterus/contra-lateral ovary preserving surgery, in combination with surgical staging of the remaining 
peritoneal surfaces +/- retroperitoneal lymph node chains (dependent upon histological subtype). In 
a large retrospective analysis, women with G3 disease or stage IC3 with clear cell histology had a 
higher risk of recurrence, but mainly related to the higher incidence of extra-ovarian spread 
observed in grade 3 tumours, rather than to a higher relapse rate in the preserved ovary.(53) 
Therefore, these patients should be carefully informed about their prognosis, to enable them to 
make a personalized and informed choice. Retrospective evidence reveals that 3.5%-11% of the 
women with unilateral disease will have contra-lateral pelvic lymph node metastases, despite 
negative ipsilateral nodes. (54, 55) 
Surgical management of primary advanced ovarian cancer 
Surgery after three cycles of chemotherapy following initial low effort or diagnostic-only surgery 
significantly lengthens progression-free and overall survival in patients with advanced disease 
compared to no further surgery. (Grade A) 
A “second look” operation with cytoreductive attempt after neo-adjuvant chemotherapy following 
upfront debulking surgery with residual disease despite maximal effort has no survival benefit and 
is not recommended (Grade A).  
The aim of cytoreductive surgery in the management of advanced stage ovarian cancer is surgical 
resection of all visible disease in patients fit enough to undergo this procedure, as this has been 
shown to be associated with an improved progression-free and overall  survival.  (Grade B) 
Neo-adjuvant chemotherapy with interval debulking surgery after three cycles of platinum based 
chemotherapy is non-inferior to primary upfront debulking surgery and adjuvant platinum-based 
chemotherapy and has reduced morbidity in patient cohorts with significant disease burden and 
low complete macroscopic tumour clearance rates or in situations where the is uncertainty about 
the possiblity of optimal removal of tumour (Grade A) 
 
Women with advanced disease should have their treatment planned by a specialist MDT at cancer 
centres having the infrastructure to support maximal surgical effort debulking with the aim of no 
macroscopic residual disease. (Grade D) 
 
Bulky lymph nodes in advanced disease should be removed, if this will complete macroscopic 
clearance, as this has been shown to significantly prolong survival and is part of the debulking. 
(Grade A) 
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In advanced epithelial ovarian cancer the aim is complete cytoreduction of all macroscopically visible 
disease, since this has been shown to be associated with a significantly increased overall and 
progression-free survival in numerous prospective and retrospective trials. (56-58) 
It is unclear whether this association is causal or whether resectable tumours are intrinsically 
biologically more chemosensitive and less likely to recur quickly.(59-61) The only evidence 
comparing maximal effort debulking surgery versus no further surgery is in the setting of interval 
debulking surgery.  The EORTC trial by van der Burg et al, which randomised 319 patients to further 
surgery versus no surgery followoing three cycles of platinum-based chemotherapy after initial 
surgery by a non-gynaecological oncologist or diagnostic surgery only.(57) The study, and 
subsequent Cochrane review which included three studies, showed that interval debulking surgery 
lengthened progression-free and overall survival only in those who had not had maximal effort at 
initial surgery. (62) The risk of death was reduced by one third in this subgroup, after adjustment for 
a variety of prognostic factors (HR = 0.68, 95% CI 0.53 to 0.87, I² = 0%).(62) 
 
In order to achieve macroscopic tumour clearance in peritoneally disseminated disease, maximal 
surgical effort is required, potentially including multi-visceral resection techniques such as peritoneal 
stripping, diaphragmatic resection, removal of bulky pelvic/ para-aortic lymph nodes, splenectomy, 
liver and/or liver capsule resection and bowel resection. Retrospective data suggest that additional 
surgical procedures do result in improved rates of cytoreduction. This requires specialist training and 
surgical expertise, as well as co-ordinated institutional effort to safely deliver.(63) Therefore women 
with advanced disease should ideally undergo such surgery in specialized centres with adequate 
infrastructure, staff and training. (64) These centres should consider keeping prospective records of 
the surgical and non-surgical management of all patients, the surgical procedures performed, the 
amount and location of any residual disease and associated morbidity and mortality. Surgery should 
be ideally performed within 2-4 weeks of decision to operate, depending on patients' wishes, co-
morbidities and prior history. 
 
The Chief Medical officer has emphasised the need for specialist surgical training and the need for a 
national audit in ovarian cancer to improve outcomes. (65) The on-going SOQCER2 study should give 
further information about the quality of life after debulking surgery. 
(https://clinicaltrials.gov/ct2/show/NCT02569983). 
  
Complete macroscopic cytoreduction is defined as macroscopic tumour clearance with no residual 
visible disease, as documented by a comprehensive visual assessment of all the areas of the 
abdomen. When complete macroscopic cytoreduction is not achievable at the time of laparotomy, 
attempts should be made to achieve near-optimal cytoreduction (<1cm residual disease) as meta-
analysis suggests that patients in whom <1cm residual disease remains have a greater overall 
survival than those with >1cm residual disease, if associated morbidity seems acceptable and 
depending on the constitution of the patient. (56)  
 
The value of systematic pelvic and para-aortic lymphadenectomy in advanced disease in the absence 
of bulky lymph nodes has not been prospectively proven to influence overall survival.  A large 
prospectively randomised trial that randomised patients with residual disease <1cm to removal of 
bulky lymph nodes only versus systematic pelvic and para-aortic LND showed that 5-year PFS could 
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be improved in the systematic LND arm; from 21.6% to 31.2% with a median of an additional seven 
months. (66) The study failed to show any overall survival benefit from a systematic LND. A large 
multicentre prospectively randomised trial of systematic pelvic and para-aortic lymphadenectomy 
extending up to the renal vessels in tumour free operated patients with advanced disease and 
without bulky lymph nodes has completed accrual (LION Trial, AGO-OVAR OP.3 [NCT00712218]) and 
the results are awaited in ASCO 2017.  
 
There is no proven value or survival benefit in second look cytoreductive surgery after three cycles of 
chemotherapy to clear any disease remaining after primary surgery performed with maximal surgical 
effort unless this paradigm was not employed upfront. (62) Similarly, a “second look” diagnostic 
laparoscopy or laparotomy after completion of treatment to assess intra-peritoneal status should 
not be routinely performed, except in the context of pertinent clinical trials, as its impact on survival 
has not been demonstrated. (67) 
6. Systemic treatment of early stage ovarian cancer (FIGO I-II) 
 
Adjuvant platinum-based chemotherapy should be discussed and offered in all cases of early 
ovarian cancer apart from low grade stage Ia/Ib. (Grade A) 
 
Two randomised, prospective trials examined the value of chemotherapy after surgery in early stage 
ovarian cancer. The ACTION and ICON1 trials included early stage cases, with grade 2/3 stage IA/B 
and all stage IC/IIA eligible. The primary analysis of ICON1, with a median follow-up of four-years, 
demonstrated a significant improvement in both relapse-free survival (RFS) (Hazard Ratio (HR)=0.65, 
95%CI=0.46-0.91, p=0.01) and overall survival (OS) (HR=0.66,95%CI=0.45-0.97,p=0.03) in favour of 
adjuvant chemotherapy with six cycles of single agent carboplatin (AUC 5/6). (68) Similar findings 
were reported in the ACTION trial in which the majority of patients received platinum-based 
combination chemotherapy. (69) 
 
A Cochrane meta-analysis of five large prospective clinical trials concluded that chemotherapy is 
more beneficial than observation in patients with early stage ovarian cancer. (70) Patients who 
received platinum-based adjuvant chemotherapy had a better OS (hazard ratio (HR) 0.71; 95% 
confidence interval (CI) 0.53–0.93] and PFS (HR 0.67; 95% CI 0.53–0.84) than patients who did not 
receive adjuvant treatment. Approximately two thirds of the cases were sub-optimally staged and 
30% of women with presumed stage 1 disease may have had undetected stage 3 disease. One 
interpretation is that the observed effect is due to the overuse of chemotherapy in cases unlikely to 
benefit compensating for the lack of complete surgical staging. However, due to concerns with 
outcome reporting bias, the Cochrane review performed an analysis of  10-year data from ACTION  
and  ICON1, which suggested that the difference between optimally and sub-optimally staged 
subgroups, in terms of deaths from ovarian cancer, was not significant (Test for subgroup 
differences: Chi² test = 2.75, df = 1, P = 0.10). Benefit for chemotherapy, even in optimally staged 
patients, could not be excluded. Adjuvant chemotherapy should be discussed with all patients with 
high risk early stage ovary cancer.  
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There is a lack of evidence supporting an additional value of targeted therapies such as 
bevacizumab, other VEGF inhibitors including nintedanib and cediranib, tyrosine kinase inhibitors 
or PARP inhibitors in early stage ovarian cancer treatment and show they should not be offered 
outside clinical trials. (Grade D)   
 
The response rate to chemotherapy in patients with non-serous epithelial ovarian carcinoma, 
including clear cell and mucinous tumours, is poor and the effectiveness of adjuvant chemotherapy 
in early stage disease in these groups may be less than HGSC. However, as patients with non-HGSC 
subtypes were not excluded from previous studies and, since there are currently no evidence-based 
alternatives for women with non-HGSC subtypes, it is remains reasonable to offer treatment as per 
HGSC.  Women with non-HGSC should be encouraged to participate in histological subtype specific 
studies, where these exist. 
7. First-line chemotherapy for advanced disease (FIGO II – IV) 
Neoadjuvant chemotherapy 
Primary debulking surgery is the standard of care where complete or optimal cytoreduction 
appears achievable in patients with good performance status. Where this is not achievable two 
randomised trials have showed non-inferiority of the neo-adjuvant chemotherapy (NAC) followed 
by interval debulking surgery. Both trials demonstrated reduction in morbidity in the NAC arm and 
an equal quality of life in both arms. (Grade A) 
 
Two prospectively randomised trials have shown that treating patients with advanced ovarian cancer 
with NAC followed by interval surgery after three cycles is no worse than first-line surgery. (58,72), 
especially in cases where performance status and/or resection is unlikely to result in an optimal 
debulking procedure and that this strategy is associated with lower surgical morbidity and mortality 
in this context. The limiting factor of both studies was that for many atients entered there was 
uncertainty about the ablity to resect tumour. ‘Ability’ to optimally resect disease relies in general 
not just on the actual surgical skills, but also the overall infrastructure, team effort,  anesthetic cover 
and institutional expertise. Both options –upfront surgery and NAC- may be discussed with patients 
with advanced disease and treatment decisions made based on the patient’s performance status, 
symptoms, co-morbidities, patient preference and quality assured institutional expertise. 
 
A Chemotherapy Response Score (CRS), based on pathological evaluation material prior to NAC and 
following it has been developed in a single centre but not yet validated in a prospective multicentre 
setting. The three-tier CRS system applied to omental samples from this initial single centre study 
showed high reproducibility (kappa, 0.67) and predicted PFS. The score also predicted sensitivity to 
first-line platinum therapy. Until validation studies are completed and the clinical benefit of the CRS 
is defined, no recommendation of its routine can be made. (74) 
Intra-peritoneal chemotherapy 
Intra-peritoneal (IP) chemotherapy can be offered within clinical trials where appropriate 
expertise and resources exist.  
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A Cochrane review of IP versus intravenous (IV) chemotherapy demonstrated an improved overall 
survival if women received an IP component to chemotherapy (eight studies, 2026 women; HR = 
0.81; 95% confidence interval (CI): 0.72 to 0.90). Intraperitoneal chemotherapy prolonged the DFI 
(five studies, 1311 women; HR = 0.78; 95% CI: 0.70 to 0.86). However, there was greater serious 
toxicity with regard to gastrointestinal effects, pain, fever and infection, but less ototoxicity with the 
IP than the IV route. (75) The improved survival with IP chemotherapy  impact has been shown to 
extend even beyond 10 years. (76) However, because of concerns over potential toxicity, due to the 
increased dose of chemotherapy given in some of the IP arms and IP catheter-related complications, 
it has not been widely adopted in Europe and is currently the subject of on-going trials the results of 
which are eagerly awaited.  Meta-analysis of the current trial data suggests that research is still 
needed to determine the optimal agent, dose and scheduling and also the value of IP therapy in the 
era of targeted maintenance tretaments. (77)  
Post operative cytotoxic chemotherapy 
The current standard of care in advanced disease is carboplatin (AUC5/6) and paclitaxel 
(175mg/m2) three-weekly for 6 cycles.  (Grade A) 
Following surgery, all patients with FIGO stage II-IV ovarian cancer should be offered platinum based 
chemotherapy +/- paclitaxel, depending on fitness. The interpretation of the results of trials that 
added paclitaxel to platinum-based drugs during the 1990s generated some controversy, but a meta-
analysis showed superiority of the combination of platinum-paclitaxel to platinum-based drugs (79). 
Carboplatin is less toxic than cisplatin and equally effective. The standard of care is three-weekly 
carboplatin (AUC5/6) and paclitaxel (175mg/m2) for six cycles. 
Dose-dense scheduling of the paclitaxel (80 mg/m2 days 1, 8, 15 every 21 days, with carboplatin AUC 
5/6 on day 1) has been shown to improve overall survival in a Japanese population. (80) A European  
phase III trial (MITO7), which randomised patients to standard dose three-weekly carboplatin 
/paclitaxel  or weekly carboplatin (AUC 2) and paclitaxel (60 mg/m2), showed no difference in PFS or 
OS, although weekly treatment was better tolerated. (81) An absence of benefit of dose-dense 
therapy may have been due to the lower dose of paclitaxel (60 mg/m2 as opposed to 80 mg/m2 
weekly) used in this study.   The ICON 8 trial, currently in follow up, has randomised over 1500 
patients to receive either three-weekly carboplatin / paclitaxel, three-weekly carboplatin and weekly 
paclitaxel (80mg/m2), or weekly carboplatin (AUC 2) and weekly paclitaxel (80mg/m2) with results 
expected during 2017. 
The addition of a third cytotoxic agent or more than six cycles has failed to show any survival 
benefit in prospectively randomised trials and is not recommended. (Grade A) (82, 83) 
 
For those patients who develop allergy to or do not tolerate paclitaxel, the combination of protein-
bound paclitaxel (Abraxane)-carboplatin or pegylated liposomal doxorubicin-carboplatin could be 
considered as alternatives. (Grade B) (84, 85)  
 
Hypersenstivity to carboplatin may occur, in which case desensitisation regimens can be useful, or 
the equally efficacious, but potentially more toxic, agent cisplatin can be used as an alternative. 
Cross-hypersensitivity to cisplatin may occasionally occur.(86) 
 
 
 
20 
Anti-angiogenics in adjuvant first-line treatment of ovarian cancer 
Targeted therapies, in addition to the conventional first line cytotoxic chemotherapy, have been 
shown to increase PFS, but not OS, when given as maintenance therapy. The addition of anti-
angiogenic therapy increases toxicity. (Grade A) 
 
Giving bevacizumab plus chemotherapy and then alone as maintenance for up to 12 months (ICON 
7) (87) or for 15 months (GOG 218) (88) following cytotoxic chemotherapy has been shown to 
prolong PFS in patients with advanced disease.  The three-arm randomised ICON8B trial opened in 
2015, building on the ICON8 trial (NCT01654146) to explore the interaction between three-weekly 
chemotherapy with bevacizumab (ICON7), carboplatin and weekly paclitaxel, and the addition of 
bevacizumab to weekly paclitaxel.  
 
The addition of other anti-angiogenic agents, including the oral tyrosine kinase inhibitors pazopanib 
and nintedanib, has also been shown to increase PFS, but not OS. Pazopanib maintenance therapy 
provided a median improvement in PFS of 5.6 months (HR 0.77; 95% CI 0.64 to 0.91; P = .0021; 
median, 17.9 v 12.3 months) in patients with advanced ovarian cancer who had not progressed after 
first-line chemotherapy in a large multicentre phase III study, but with increased treatment-related 
Grade 3 or 4 adverse events. The schedule has not been submitted for EMA licensing. (90) 
Nintedanib in combination with carboplatin and paclitaxel has also been demonstrated to be an 
active first-line treatment that increases PFS in a recent large multicentre phase III trial, but is 
associated with more gastrointestinal adverse events. (91) 
First-line chemotherapy in non-serous histological subtypes 
Currently no evidence to support the use of drugs other than platinum-taxane for non-serous 
histological subtypes (Grade A) 
The efficacy of conventional chemotherapy in rarer histological subtypes, including low-grade 
endometrioid and mucinous subtypes, has been shown to be less effective.(92) Nevertheless, all 
large phase III randomised chemotherapy trials so far have included all histological subtypes. It has 
been difficult to conduct randomised trials in rarer histological subtypes. However, a Japanese-led 
trial in clear cell cancer has recently been published, showing no difference between standard 
chemotherapy and cisplatin-irinotecan. (93)  
In mucinous tumours, an even rarer subtype, an international randomised trial was abandoned due 
to poor accrual. Currently there is no evidence to support the use of drugs other than 
carboplatin/paclitaxel in these histological subtypes. Furthermore the role of adjuvant conventional 
chemotherapy in early stage tumours with rare histological subtypes remains unclear. Currently, 
decision-making is often based on larger trials that contain patients with these subtype tumours.  
The national prospective observational study of rare neoplasias of gynaecological origin (RANGO) will 
allow the collection of information about tumours in the future.  In time, this project will link in with 
an international Gynaecological Cancer Inter-Group mega-database initiative. 
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8. Follow-up 
 
A careful history, assessment of new and potentially tumour-related symptoms and clinical 
examination is essential at follow up visits. (Grade C) 
 
CA125 measurement is not mandatory and has not been proven to be of survival benefit. (Grade 
A) 
 
Patients should have the contact details of their key worker so that they access an early review for 
unexpected symptoms. (Grade D) 
 
Follow-up along a traditional hospital-based model provides opportunities to assess the risk and/or 
presence of recurrence and to  assess patients holistically for the presence of on-going physical, 
psychological, emotional, financial and sexual survivorship issues related to their cancer treatment. 
 
The intervals between follow-up visits vary according to local practice, but the most common 
schedule through convention is every 3 months for the first 2 years and then every 6 months up to 5 
years after end of treatment, despite a lack of randomised trial data illustrating a benefit of strict 
follow-up protocols over an individualized patient- and symptom-led approach.  
 
Increases in CA125 may herald progressive disease in patients who achieve a normal CA125. A 
prospectively randomised MRC/EORTC trial demonstrated no difference in overall survival after a 
median follow-up of 56.9 months (HR 0.98, 95% CI 0.80 to 1.20; P = 0.85)  between patients who 
received chemotherapy based on a rising CA125 and those who did not receive chemotherapy until 
they were symptomatic. Treatment based on an abnormal CA125 led to early treatment by a median 
of 4.8 months. (94), (95).  Interestingly, those in the arm where treatment was initiated on CA125 
rise had a shorter interval to deterioration in global health score or death (HR 0.71, 95% CI 0.58 to 
0.88; P value < 0.01).  This finding led to many questioning the clinical and cost-effectiveness of 
routine CA125 measurements in follow-up. Despite this, some patients may wish to know what 
might lie ahead and for some a rise in CA125 might indicate surgically-resectable disease recurrence, 
while for others it may trigger imaging that will determine timing and value of further treatment 
(96). In addition, participation in first-line trials normally requires regular post-treatment CA125 
measurements for trial end points. However, it is now accepted that a rising CA125 alone, without 
clinical or radiographic evidence of recurrence, should not be routinely be used as an indication to 
commence systemic chemotherapy. 
 
The results of the prospectively randomised DESKTOP III (NCT01166737) and GOG 0213 
(NCT00565851) trials may potentially change current follow up recommendations, if secondary 
debulking surgery is shown to be associated with improved survival and becomes a standard of care. 
Emerging maintenance therapies such as immunotherapy may also require changes in current follow 
up arrangements in the future. 
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9. Management of recurrent disease 
Surgical treatment of recurrent disease 
Cytoreductive surgery could be offered to patients with platinum-sensitive ovarian cancer relapse 
where the disease appears completely resectable in patients with a good performance status, as 
this has shown to be associated with improved OS and PFS in retrospective studies and meta-
analyses;  patients should however be aware that the disease will remain chronic, and that no 
prospective trials have yet proven a survival benefit. (Grade C)  
 
Palliative surgery for bowel obstruction could be discussed after failure of conservative treatment 
and after careful consideration of the patient's overall prognosis, quality of life, previous 
treatments, future therapeutic options and co-morbidities.  Iatrogenic induced short bowel 
syndrome with the necessity of long life total parenteral nutrition should be avoided and plans for 
surgery should be agreed within a specialist MDT. (Grade C) 
 
The value of surgery for relapsed ovarian cancer on overall survival in patients with EOC has not yet 
been established in prospectively randomised trials, but when complete tumor removal can be 
achieved, retrospective studies have shown a significantly longer OS and PFS when compared to 
women with residual disease following surgery for relapse. This survival benefit persists even in 
multifocal relapse and peritoneal carcinosis as long as complete tumor clearance is achieved (97-
100).  
 
Careful consideration of cases within a specialist MDT can identify individuals whose disease may 
benefit from a surgical approach. In a large, retrospective, systematic trial (DESKTOP I), patients with 
two out of three of complete resection at first surgery, good performance status and absence of 
ascites, had an improved survival. (97)  No RCT-level data were identified in systematic reviews. (101, 
102)  Four prospective multicentre randomised trials evaluating the value of surgery at relapse are 
now underway: DESKTOP III [NCT01166737] used the selection criteria detailed above and is in 
follow up, GOG 213 [NCT00565851] incorporates the addition of bevacizumab to chemotherapy, 
SOC1 [NCT01611766] from the Shanghai Gynecologic Oncology Group, and the SOCceR from the 
Netherlands [NTR3337]. The results of these prospective trials will define the value of cytoreductive 
surgery at relapse.  
 
EOC patients often present with symptoms of acute or sub-acute bowel obstruction at relapse, often 
attributable to diffuse peritoneal dissemination of recurrent tumour rather than a single point of 
obstruction. The implementation of novel targeted therapies with anti-angiogenic potential may 
favour fistula formation or intestinal perforation and so recurrent EOC, with the potential to be 
complicated by such severe and acute events, constitutes a therapeutic dilemma.(103) No RCTs exist 
comparing surgical and medical management, and evidence that showed a benefit to surgery over 
octreotide was of low quality. (104) In a retrospective review of 90 patients who underwent surgery 
for bowel obstruction in relapsed ovarian cancer, the median OS was 90.5 days (range, <1 day-6 
years). (105) Palliative surgery in patients with gastrointestinal and other symptoms of ovarian 
cancer recurrence therefore requires multidisciplinary consideration.(100, 105)   Any perceived 
benefits should be carefully balanced against the risks for each individual patient and factors such as 
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co-morbidities, baseline quality of life, previous response to chemotherapy, length of treatment 
intervals and patient wishes are likely to be crucial. The management of these cases should be led by 
specialist gynaecological multidisciplinary teams, including palliative care input at an early stage. If 
surgery is planned, intra-operative input from gynaecological oncologists is important, so that 
likelihood of chemotherapy responses after palliative surgery is considered when making intra-
operative decisions.  
 
Endoscopic techniques, such as placement of intestinal stents and percutaneous endoscopic 
gastrostomy (PEG), may allow the palliation of gastrointestinal symptoms with reduced procedure-
related morbidity in selected patients.  
 
Surgical intervention should be restricted to cases where there is a distal mechanical bowel 
obstruction and where the formation of a proximal high output small bowel stoma is not likely to be 
necessary, as such high output stomas significantly reduce quality of life and require permanent total 
parenteral nutrition (TPN). Pre-operative imaging demonstrating the most proximal point of bowel 
obstruction should be used to identify patients with a level of obstruction at high risk of iatrogenic 
short bowel syndrome. Management of patients with bowel obstruction should ideally happen 
within multi-disciplinary teams with experience in managing such cases. (106) 
Systemic treatment of recurrent disease 
In patients with longer treatment free intervals (TFI) (> 6 months), combination therapies with 
platinum re-challenge are recommended. (Grade A) 
 
In patients with short TFIs (<6months) single agent therapy is equally effective and less toxic than 
combination therapies. (Grade A) 
 
Along with patient factors, including patient choice and performance status, residual toxicities and 
prior hypersensitivity reactions, the most important factors that inform the choice of chemotherapy 
for relapsed ovarian cancer are the TFI and platinum-free interval (PFI). The conventional definition 
of platinum sensitivity is a PFI of greater than six months  after cessation of the last platinum-based 
chemotherapy course and was based on the likelihood of disease response to platinum re-treatment 
in older studies. (107, 108)  However, in an era of more accurate imaging techniques and 
maintenance regimens, this definition is more complex with the conventional definition of platinum-
sensitive disease becoming less useful clinically (Table 1). (109) 
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Table 1 The Gynecologic Cancer Intergroup (GCIG) (162) categorisation of patients based on the 
length of remission following platinum-based chemotherapy. The platinum-free interval is however 
somewhat theoretical and in real-life exists as a spectrum 
 
 
While the duration of response to platinum is important, retrospective data also suggest that seeking 
to extend the platinum-free interval itself may also help improve the patient’s subsequent response 
to platinum re-treatment and there are now several studies supporting this concept.(110, 111) In 
patients with platinum-sensitive or partially platinum-sensitive ovarian cancer recurrence  (6-12 
months PFI) published clinical evidence reports response rates to second-line therapy ranging 
between 27% and 33%, regardless of whether platinum-based or non-platinum drugs are used.  
However, response rates can be a poor measure of benefit, which is better expressed in terms of PFS 
and combination therapy (such as carboplatin / paclitaxel, carboplatin / liposomal doxorubicin or 
carboplatin / gemcitabine) would be recommended as this improves PFS and OS in this group of 
patients. (107, 112, 113)  Trabectedin and pegylated liposomal doxorubicin (PLD) have been shown 
to be more beneficial compared with PLD alone, especially in the group of patients with partially 
platinum-sensitive disease. The addition of bevacizumab to relapse chemotherapy in the platinum 
sensitive setting and as maintenance afterwards also increases PFS compared with combination 
carboplatin / gemcitabine alone (85, 114).  
 
In the platinum refractory / resistant setting there does not appear to be any advantage in using 
combination therapies, which are associated with higher rates of adverse events.  In the platinum-
resistant setting, second-line single-agent chemotherapy with non-platinum drugs (such as PLD, 
weekly paclitaxel, etoposide or topotecan) results in short-lived response rates of approximately 10% 
to 25% and PFS of 4-5 months and OS of 12-13 months (96). However, the addition of bevacizumab 
to conventional chemotherapy has been shown to increase PFS to 6.7 months, with OS of 16.6 
months compared to monotherapy (PLD, weekly paclitaxel or topotecan) and improved patient-
related outcomes in a carefully selected population (115). If the patient cannot tolerate 
chemotherapy and/or symptoms are not requiring a rapid response to chemotherapy, then 
hormonal treatment could be an alternative, although evidence for benefit is limited. (116, 117) 
 
Palliative radiation may have a role in highly selected situations. 
  
Classification Definition 
Platinum Sensitive (PS) Progress with an interval of > 12 months after completion of 
chemotherapy 
Partially PS (pPS) Progress with an interval of between 6-12 months after 
completion of chemotherapy 
Platinum Resistant (PR) Progress with an interval of less than 6 months after completion of 
chemotherapy 
Platinum Refractory 
(PRef) 
Progress during, or within 4 weeks after completion of 
chemotherapy 
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10. Other epithelial histological subtypes 
Low Grade Serous Ovarian Cancer (LGSOC) 
Surgery is the most effective management for LGSOC, which has a lower response rate to 
chemotherapy than HGSOC. (Grade B) 
 
There is a 25% response rate seen with a platinum-taxane regimen in LGSOC and given the lack of 
a superior alternative chemotherapy regimen, this can be offered in patients with advanced 
disease.(Grade B) 
 
LGSOC constitutes about 5% of all serous carcinomas, occurs in younger women and is characterised 
by a uniform population of cells arranged typically in papillary clusters and showing sparse mitotic 
activity (118). Neither necrosis nor P53 mutation are features of LGSOC. (119) 
The management of LGSOC is predominantly surgical.  Primary surgery aims to remove all visible 
disease and may be considered again at relapse. A large meta-analysis showed a response rate to 
platinum based chemotherapy of approximately 24% in patients with advanced primary low grade 
advanced ovarian cancer after upfront surgery, and hence lower than for their high grade serous 
counterparts (120). The authors concluded that HGSOC and LGSOC differ with respect to 
chemosensitivity, chemotherapy being of considerably less benefit in patients with LGSOC than 
patients with HGSOC, growth pattern and outcome following surgery.   Hormonal maintenance 
strategies in LGSOC after completion of platinum based chemotherapy seem to have a survival 
benefit in retrospective series (121).  
International multicentre studies are urgently needed and recruitment to these is important, as is 
registration of cases onto rare tumour databases to facilitate the study of this rare condition. (122) 
Mucinous carcinoma of the ovary 
True advanced mucinous tumours of primary ovarian origin are rare and effective systemic 
management / treatment strategies are limited. (Grade B).   
 
Ovarian metastases from primary mucinous tumours of other organs such as GI tract should be 
excluded. (Grade B) 
 
Mucinous histologies account for 3 – 5% of all ovarian carcinomas. They are typically confined to the 
ovary at presentation, are large and show a continuum of architectural features including benign, 
borderline and malignant areas. Confluent and expansile patterns of invasion are often seen, but 
when an infiltrative pattern is present, the pathologist must be alert to the possibility of a metastatic 
carcinoma from another site. Invasive mucinous carcinoma with an infiltrative pattern has a more 
aggressive course than mucinous carcinoma with an expansile pattern. Mucinous carcinomas of the 
ovary usually exhibit a CK7+/CK20-/CDX2- immunoprofile. 
Advanced mucinous tumours, with intra-peritoneal involvement, are unlikely to be of ovarian origin 
as these are rare. (123) Many of these are Krukenberg tumours or arise from other organs, such as 
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the appendix. Ovarian tumours metastatic from appendiceal primaries may have morphological 
features of mucinous borderline tumours and the presence of dissecting mucin in the peritoneal 
cavity (psuedomyxoma peritonei) favours this diagnosis. Rarely advanced mucinous tumours can 
arise from an ovarian teratoma. 
 
Surgery with adequate peritoneal staging is the standard treatment for the majority of primary 
mucinous ovarian tumours.   Fertility-sparing surgery should be considered in young women with 
unilateral disease. The management of advanced true primary ovarian mucinous tumours is 
challenging, as they are not particularly chemo-responsive.  The collection of pathological and clinical 
data from patients with these rare tumours is vital to allow progress to be made in determining 
appropriate therapeutic strategies. (124) Patients with advanced disease are usually treated with 
carboplatin and paclitaxel, although these tumours respond less well to this combination than the 
more common non-mucinous tumours. mEOC (NCT01081262), a randomised trial comparing 
carboplatin and paclitaxel, oxaliplatin and capecitabine +/- bevacizumab (a regimen used in 
gastrointestinal tract cancers) closed early due to poor recruitment. 
 
Where metastasis from the gastro-intestinal (GI) tract must be excluded, bidirectional GI endoscopy 
should be performed and referral to a GI MDT should be considered.  
Other subtypes 
Rarer carcinoma subtypes include malignant Brenner tumour, sero-mucinous carcinoma and 
undifferentiated carcinoma, and transitional cell carcinomas. (125) Mesenchymal tumours that occur 
in ovaries include endometrial stromal sarcomas and various other sarcomas.  In addition, multiple 
different histological subtypes of cancer can also arise from within mature teratomas, such as 
squamous cell carcinoma (126) and carcinoid tumours. (127) 
Mixed epithelial and mesenchymal tumours 
Adenosarcoma is a rare biphasic tumour of the ovary composed of malignant mesenchymal and 
benign epithelial elements.  
Carcinosarcoma is a more common neoplasm, composed of malignant epithelial and mesenchymal 
elements. Molecular studies indicate that the sarcomatous components of the neoplasms arise from 
carcinomatous components. High-grade serous carcinomas and carcinosarcomas share several 
molecular abnormalities including aberrant P53 expression and occasional germline mutation of 
BRCA2. (36, 37)  
Wolffian tumour 
Previously termed female adnexal tumour of Wolffian origin (FATWO), this is an uncommon tumour 
that is presumed to arise from the Wolffian remnants in the adnexal region. The tumour is usually 
benign and composed of cysts of varying size with sieve like areas admixed with solid and spindled 
areas. 
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Small cell carcinoma of the ovary (SCCO) 
Four types of small cell carcinoma of the ovary are recognised: hypercalcaemic and pulmonary 
subtypes (SCCOHT and SCCOPT), as well as a large cell variant, which can be difficult to distinguish 
from the other two, and the classical carcinoid.  Overall these are rare and highly malignant tumours 
that typically occur in young women.  The tumours are usually unilateral with extra-ovarian spread in 
nearly 75% of cases at the time of presentation. (128) Yong and colleagues found that only 33% of 
women presenting with stage I SCCO were alive and disease free at an average of 5.7 years’ follow 
up and no patients with advanced disease survived. (129) A diffuse growth pattern, with foci of 
follicle-like spaces, is typical. The lining cells are monotonous, showing high grade atypia, brisk 
mitotic activity and necrosis. On immunohistochemistry (IHC), the cells stain positive for WT1 with 
focal staining for epithelial markers. It has been shown very recently that the cells in SCCOHT are 
characterised by inactivation of the SMARCA4 gene (encoding the BRG1 protein) resulting in a loss of 
BRG1 protein expression on IHC. (130) This means that a cohort of the patients with so-called 
“ovarian” small cell carcinoma have a malignant rhabdoid tumour and maybe a strategy for 
identifying SCCOHT from SCCOPT and larger cell variants. (131) It is accepted that the patients with 
small cell ovarian cancer have a dismal prognosis. There maybe some evidence for considering pelvic 
radiotherapy (RT) for those with early stage disease following surgery but this has not been validated 
in prospective randomised trials. (132) For those with advanced disease or relapse, chemotherapy 
schedules are generally extrapolated from those used in small cell lung cancer and generally include 
a platinum-based agent and etoposide, although more intense treatment strategies have also been 
investigated. (133) (134)  
All of the above more unusual subtypes of ovarian cancers tend to be managed in the same way as 
serous epithelial ovarian carcinoma, earlier stages clearly benefiting from surgery in the first 
instance. The introduction of a national rare gynaecological tumour database to assimilate the 
treatments and outcomes of these patients prospectively will be integral to any progress in 
managing these rarer malignancies. 
Metastatic carcinoma including Krukenberg tumours 
Metastasis to the ovary is not an uncommon phenomenon where it may represent the clinical 
sentinel site of a metastatic cancer. Gross features suggesting metastases are small size, bilaterality, 
nodular appearance and involvement of the ovarian surface. Microscopic features favouring 
metastases are an infiltrative growth pattern, stromal desmoplasia, necrosis, hilar and vascular 
involvement and IHC may assist in determining the primary site of a metastatic mucinous carcinoma. 
The commonest primary cancer sources (other than from the endometrium or cervix) are colorectal, 
gastric, pancreaticobiliary and appendicular adenocarcinomas (the appendix may also be the primary 
site of a borderline mucinous tumour, which progresses rarely to pseudomyxoma peritoneii). 
Krukenberg tumours are particular ovarian metastases, characterised by bilateral solid ovarian 
masses, microscopically demonstrating replacement of the ovarian stroma by signet ring, mucinous 
cells. The primary site is most often gastric or breast, where similar signet ring mucinous cells are 
seen. 
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11. Borderline ovarian tumours (BOT) 
 
Complete surgical resection and adequate peritoneal surgical staging has been shown to be 
associated with a longer PFS in patients with Borderline tumours. (Grade B) 
 
Borderline ovarian tumours with “invasive” peritoneal implants are reclassified as low grade 
ovarian cancers under the new FIGO classification of 2014. 
 
Pelvic and para-aortic lymph node sampling to stage cases of BOT is not recommended in the 
absence of bulky lymph nodes. (Grade B) 
 
It is safe for young patients with BOT to receive fertility sparing surgery but given the higher risk of 
relapse within any remaining ovarian tissue, regular sonographic follow up is recommended. 
(Grade B) 
 
There is no evidence-based indication for cytotoxic chemotherapy in BOT. (Grade B) 
 
Ovarian epithelial tumour classification is characterised by its unique category of borderline tumours. 
Although the morphology of these tumours includes no invasive characteristics, clinically their 
behaviour is not always entirely benign. While borderline endometrioid, clear cell, Brenner tumours 
and correctly diagnosed mucinous borderline tumours usually behave in benign fashion, the serous 
and sero-mucinous have a distinct behaviour, which is not always benign. 
Serous borderline tumours (SBTs) 
These tumours show a typical hierarchical branching pattern lined by cells that show low grade 
nuclear atypia.  When clusters of cells less than 5 mm in greatest dimension, typically with a 
surrounding clear space, are seen in the stroma, the term microinvasion is applied.  Microinvasion is 
seen more commonly in pregnant patients  but the presence of microinvasion does not alter the 
outcome. (135) Women with stage I disease have the same outcome as the general population, 
irrespective of microinvasion. (136)  
 
SBTs can also be associated with peritoneal lesions that are termed implants. When the implants are 
confined to peritoneal/ mesothelial lined surfaces and lack invasion of underlying tissue, they are 
termed non-invasive implants. Where there is invasion of the underlying fat or muscle, the term 
invasive implants is used. In some instances, unequivocal invasion is not demonstrable, but the 
lesion displays the cytological features of invasive implants. (137) The WHO 2014 classification 
recommends that because these lesions with invasive implants may behave like LGSOC, they should 
be designated as such.  Finally SBTs with micropapillary and microacinar architecture have a greater 
association with extra-ovarian disease and a higher incidence of recurrence and death from disease 
than typical SBTs. (138) Morphologically, micropapillae typically lack stromal cores and hierarchical 
branching. They are composed of cells that are cuboidal, have a high nuclear cytoplasmic ratio and 
form finger like protrusions that are at least five times longer than broad.  
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Mucinous borderline tumours (MBTs) 
MBTs typically present as large unilateral masses that are confined to the ovary. There are no well-
documented cases of MBTs with implants. Adequate sampling of these tumours is crucial, since they 
are typically heterogenous and can harbour occult foci of carcinoma. (139) MBTs are lined by 
mucinous epithelium with varying degrees of stratification, tufting and papillary formation. When 
the lining cells are markedly atypical the term MBT with intraepithelial carcinoma is used. MBT with 
microinvasion is defined as small foci of microinvasion less than 5 mm in greatest linear dimension. 
(140) These features do not appear to affect prognosis adversely in stage 1 tumours. (141) 
 
Non-ovarian mucinous tumours, including metastatic ovarian mucinous tumours associated with 
pseudomyxoma peritonei and metastatic mucinous carcinomas (Krunkenberg tumours) with a 
deceptive pattern of invasion, are recognized as tumours that can simulate primary MBTs. (142)  
Clinical management of borderline ovarian tumours  
Complete macroscopic tumour resection should be the aim of all surgery for BOT, with adequate 
surgical staging especially in apparent stage 1 disease including peritoneal biopsies, cytology and 
omentectomy (with appendicectomy for mucinous tumours). [Grade B] 
 
A fertility sparing approach in young patients does not preclude adequate peritoneal staging since, 
even in the presence of peritoneal implants, peritonectomies with preservation of at least one ovary 
and tube and uterus, can be performed. Adequate surgical staging at initial presentation of the BOT 
is a defining factor predicting progression-free and overall survival. However, the diagnosis is often 
made retrospectively following surgery by a non-gynaecological oncologist.  Two large retrospective 
series of women with BOT showed that, higher stage, incomplete staging, residual tumour, and 
fertility-sparing surgery were independent prognostic factors for recurrence. (136, 143, 144) Patients 
should be informed about the risks and benefits of completion staging after simple cystectomy or 
unilateral salpingo-oopherectomy with an incidental finding of BOT. Simple cystectomy in an ovary 
with BOT carries a risk of relapse and so should be considered mainly for fertility-sparing reasons and 
after thorough informed consent. (145)   Longer-term, the risk of malignant transformation was low 
overall (~2%),  but was found in 30% of those with relapsed disease, although was much less 
frequent in women under 40 years of age at original diagnosis, compared to those aged over 40 
years (12.0% versus 66.7%, P < 0.001). Completion surgery could be discussed with women once they 
have competed their families, even though there are no data to support this having any impact on 
OS or PFS. 
In early stages, with small volume masses and in the absence of extensive peritoneal implants, 
laparoscopic management is as safe as laparotomy from an oncological point of view. Hysterectomy 
has no value in complete staging of a patient with BOT.  Hysterectomy should be considered if the 
patient wishes, or for cytoreduction if the uterus is involved with invasive disease. (143) 
 
There is no value in lymph node sampling or dissection in BOT and this should therefore not be 
routinely performed, although, if bulky lymph nodes are present they should be removed. There is 
no proven value of cytotoxic chemotherapy in patients with BOT. (143, 146) BOT can relapse decades 
after the initial diagnosis, and is uncommon in those who have had both ovaries removed.  The most 
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significant risk factor for relapse was the presence of invasive peritoneal implants, however since this 
group of patients now belongs to the ones with low grade ovarian cancer, the remaining BOT group 
is prognostically very favourable. For that reason value of follow up in patients with early disease and 
after bilateral BSO remains unscertain. However,  follow up is essential in patients after fertility-
sparing surgery since they have a significantly higher risk of relapse in the remaining ovaries. There is 
no value in the routine CA125 based follow up for BOT patients (143). Relapse of borderline disease 
should be mainly treated surgically, if disease seems operable, since response to chemotherapy is 
poor. 
12. Support needs for women with ovarian cancer 
Women with EOC who require elective surgery in the NHS should have access to a holistic 
assessment by a clinical nurse specialist (Grade D). 
The ovarian cancer pathway is a complex process that includes recognizing abnormal symptoms, 
worrying that you may have cancer, developing acute symptoms, having tests and investigations, 
been told that you may have cancer, having cancer confirmed, treatments that include extensive 
surgery, multiple chemotherapy agents and courses, the potential shortening of ones life, carrying a 
gene that may affect children and grandchildren, and facing death. Women with ovarian cancer have 
some or all of these experiences and other related experiences. Women with ovarian cancer report 
the significant physical and emotional impact of the disease on quality of life (147-151) and the 
needs of cancer patients often go unmet. (151-153)  
Supporting women effectively during the diagnostic, treatment and post treatment phases involves 
managing the physical, psychological and social impact of the disease and its treatment.  
In line with NICE guidelines (2) , women with ovarian cancer should be offered information about 
their disease (including the stage of the disease, treatment options and prognosis, management of 
side effects, sexuality, fertility, menopause management, signs and symptoms of recurrence, genetic 
information, self-help strategies, and dealing with emotions).  This should  include the amount of 
detail they want and are able to deal with in a suitable format, including written. 
Assessing individual patient need is the cornerstone of patient-centred care. The information and 
support provided should enable women to make decisions about their care and how it will affect 
their lives from the time of suspected cancer and diagnosis. Decisions made during this time will 
impact on immediate treatment and side effects, quality of life and post-treatment consequences. 
The National Cancer Survivorship Initiative (NCSI) in England was set up to improve cancer care from 
the point of diagnosis and recommended the provision of a Holistic Needs Assessment (HNA) for all 
cancer patients at least at the time of diagnosis and end of treatment. (154) This should include a 
care plan tailored to individual need. Effectively assessing individual needs and concerns can lead to 
early interventions and open up communication based on partnership, empowering the patient 
towards self-management, and the confidence and permission to access available help and support. 
The HNA should be a formal process, best led by a framework or tool to ensure that physical, 
psychological, spiritual, emotional and social domains are considered, and documented to develop 
an individualised care plan that can be shared with other healthcare professionals, as appropriate. 
(154) The HNA, together with a treatment summary, a cancer care review and a health and wellbeing 
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event are key elements of the Recovery Package which, when delivered together, can improve 
outcomes for people living with and beyond cancer. (155) 
Women undergoing surgery may also benefit from being treated within an Enhanced Recovery 
Programme (ERP), a multimodal perioperative care enhancement protocol designed to improve 
patient outcomes and speed recovery. (156) There is qualitative evidence to support ERP in women 
with gynaecological cancer but no evidence to date from high-quality studies specific to  
gynaecological oncology surgery(157-159), however, data from a colorectal surgery RCT support this 
approach. (160)  The ERP focuses on making sure that patients are active participants in their own 
recovery process and focuses on four elements:  
• Pre-operative assessment, planning and preparation before admission 
• Reducing the physical stress of the operation 
• Structured approach to immediate post-operative and during (perioperative) management, 
including pain relief 
• Early mobilisation 
Effective supportive care involves patient involvement in the care process, and identification and 
management of individual supportive care needs, to maximise quality of life. Focusing on these 
needs is a key function of the cancer Clinical Nurse Specialist (CNS). The high-level activities of the 
cancer CNS can be separated into four main areas; having technical knowledge to oversee and co-
ordinate services to personalise the cancer pathway for individual patients, being the key accessible 
professional for the multidisciplinary team, assessing and alleviating psychosocial suffering including 
referral as necessary and ensuring services are responsive to patient need.  Access to a cancer CNS 
has been shown to improve patient experience. 
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13. Appendices 
 
Appendix A 
Grades of recommendations 
 
Strength  
A At least one meta-analysis, systematic reviews or RCT’s rated as 1++ and directly 
applicable to the patient population or 
A systematic review of RCTs or a body of studies rated as 1+ directly applicable to 
the patient population and demonstrating consistency of results. 
B Evidence from Level 2++ studies directly applicable to the patient population or 
extrapolated from level 1 studies. 
C Evidence from Level 2+ studies directly applicable to the patient population or 
extrapolated evidence from studies rated at 2++. 
D Evidence from Level 3 or 4 studies or extrapolated evidence from studies rated as 
2+. 
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Appendix B 
Establishing the diagnosis in secondary care (modified from NICE CG122)  
 
 
 
Diagnosis and 
Preoperative testing
- Calculate Risk of 
Malignancy Index
- for women under 40 
years, check serum 
Beta HCG, AFP, LDH to 
exclude germ cell 
tumours
RMI ≥250 refer to 
gynaecological 
cancer centre 
specialist MDT 
Perform CT scan 
abdomen and pelvis 
for staging if clinical 
features, CA125 and 
pelvic ultrasound 
suggestive of Ovarian 
cancer. CT chest may 
be performed  for 
staging.
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Appendix C 
2014 FIGO ovarian, fallopian tube, and peritoneal cancer staging system and corresponding TNM 
(161) 
Stage I. Tumour confined to ovaries or fallopian tube(s) 
FIGO staging 
2009 
TNM staging Description 
FIGO IA T1a-N0-M0 Tumour limited to one ovary (capsule intact) or fallopian tube; 
no tumour on ovarian or fallopian tube surface; no malignant 
cells in the ascites or peritoneal washings 
FIGO IB  T1b-N0-M0 Tumour limited to both ovaries (capsules intact) or fallopian 
tubes; no tumour on ovarian or fallopian tube surface; no 
malignant cells in the ascites or peritoneal washings 
FIGO IC1 T1c N0-M0 Tumour limited to one or both ovaries or fallopian tubes, with 
surgical spill 
FIGO IC2  T1c-N0-M0 Tumour limited to one or both ovaries or fallopian tubes, with 
capsule ruptured before surgery or tumour on ovarian or 
fallopian tube surface 
FIGO IC3  T1c-N0-M0 Tumour limited to one or both ovaries or fallopian tubes, with 
malignant cells in the ascites or peritoneal washings 
 
Stage II. Tumour involves one or both ovaries or fallopian tubes with pelvic extension (below 
pelvic brim) or primary peritoneal cancer 
FIGO IIA T2a-N0-M0 Extension and/or implants on uterus and/or fallopian tubes 
and/or ovaries 
FIGO IIB T2b-N0-M0 Extension to other pelvic intraperitoneal tissues 
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Stage III. Tumour involves one or both ovaries or fallopian tubes, or primary peritoneal cancer, 
with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or 
metastasis to the retroperitoneal lymph nodes. 
FIGO IIIA1  
 
FIGO IIIA1(i)  
FIGO IIIA1(ii)  
 
T1/T2-N1-
M0 
Positive retroperitoneal lymph nodes only (cytologically or 
histologically proven) 
Metastasis up to 10 mm  
Metastasis more than 10 mm 
FIGO IIIA2 T3a2-N0/N1-
M0 
Microscopic extrapelvic (above the pelvic brim) peritoneal 
involvement with or without positive retroperitoneal lymph nodes 
FIGO IIIB T3b-N0/N1-
M0 
Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm in 
greatest dimension, with or without metastasis to the 
retroperitoneal lymph nodes 
FIGO IIIC T3c-N0/N1-
M0 
Macroscopic peritoneal metastasis beyond the pelvis more than 2 
cm in greatest dimension, with or without metastasis to the 
retroperitoneal lymph nodes (includes extension of tumour to 
capsule of liver and spleen without parenchymal involvement of 
either organ) 
 
Stage IV. Distant metastasis excluding peritoneal metastases 
FIGO IVA Any T, any N, M1 Pleural effusion with positive cytology 
FIGO IVB Any T, any N, M1 Parenchymal metastases and metastases to extra-abdominal 
organs (including inguinal lymph nodes and lymph nodes 
outside of the abdominal cavity) 
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Appendix D 
Risk of Malignancy Index I (RMI I) calculation 
RMI I combines three pre-surgical features: serum CA125 (CA125), menopausal status (M) and 
ultrasound score (U). The RMI I is a product of the ultrasound scan score, the menopausal status and 
the serum CA125 level (IU/ml). (31) 
RMI I = U x M x CA125  
The ultrasound result is scored 1 point for each of the following characteristics: multilocular cysts, 
solid areas, metastases, ascites and bilateral lesions.  
U = 0 (for an ultrasound score of 0) 
U = 1 (for an ultrasound score of 1) 
U = 3 (for an ultrasound score of 2–5) 
The menopausal status is scored as 1 = pre-menopausal and 3 = post-menopausal. 
The classification of ‘post-menopausal’ is a woman who has had no period for more than 1 year or a 
woman over 50 who has had a hysterectomy.  
Serum CA125 is measured in IU/ml and can vary between 0 and hundreds or even thousands of 
units. 
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